Krebs Biochemicals & Industries Ltd
Incorporated in 1991, Krebs Biochemicals & Industries Ltd is presently engaged in manufacturing of active pharmaceutical ingredients.
- Market Cap ₹ 156 Cr.
- Current Price ₹ 72.4
- High / Low ₹ 94.0 / 59.2
- Stock P/E
- Book Value ₹ -50.3
- Dividend Yield 0.00 %
- ROCE -28.6 %
- ROE %
- Face Value ₹ 10.0
Pros
Cons
- Company has low interest coverage ratio.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2012 | Jun 2013 | Sep 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
69 | 11 | 0 | 0 | 1 | 3 | 34 | 48 | 33 | 54 | 60 | 52 | 50 | |
73 | 24 | 4 | 5 | 14 | 11 | 41 | 58 | 52 | 71 | 94 | 68 | 60 | |
Operating Profit | -4 | -13 | -4 | -5 | -12 | -8 | -8 | -10 | -19 | -18 | -34 | -16 | -10 |
OPM % | -5% | -117% | -1,088% | -248% | -22% | -20% | -56% | -33% | -57% | -30% | -20% | ||
3 | 6 | 0 | 3 | 1 | -0 | -1 | 0 | 0 | 1 | 1 | 1 | 0 | |
Interest | 9 | 1 | 0 | 4 | 1 | 3 | 5 | 6 | 6 | 6 | 5 | 3 | 4 |
Depreciation | 10 | 8 | 0 | 2 | 4 | 4 | 4 | 4 | 5 | 5 | 6 | 7 | 7 |
Profit before tax | -19 | -16 | -4 | -8 | -16 | -16 | -18 | -20 | -29 | -28 | -45 | -25 | -21 |
Tax % | 10% | 5% | -10% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | |
-17 | -15 | -4 | -8 | -16 | -16 | -18 | -20 | -29 | -28 | -45 | -25 | -21 | |
EPS in Rs | -15.17 | -13.22 | -3.78 | -6.82 | -10.33 | -9.67 | -10.73 | -12.03 | -16.04 | -14.45 | -20.65 | -11.45 | -9.66 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | 9% |
3 Years: | 16% |
TTM: | -17% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | -12% |
3 Years: | 5% |
TTM: | 28% |
Stock Price CAGR | |
---|---|
10 Years: | 13% |
5 Years: | -7% |
3 Years: | -15% |
1 Year: | -1% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
Last Year: | % |
Balance Sheet
Figures in Rs. Crores
Mar 2012 | Jun 2013 | Sep 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 10 | 10 | 10 | 10 | 13 | 14 | 14 | 17 | 18 | 20 | 22 | 22 | 22 |
Reserves | 14 | -2 | -6 | 5 | -4 | -12 | -32 | -31 | -43 | -67 | -97 | -121 | -130 |
Preference Capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 30 | 30 | 130 | 130 | |
86 | 93 | 93 | 61 | 31 | 48 | 56 | 53 | 36 | 81 | 13 | 53 | 188 | |
39 | 37 | 41 | 33 | 77 | 73 | 87 | 103 | 123 | 125 | 252 | 221 | 99 | |
Total Liabilities | 149 | 138 | 138 | 108 | 116 | 122 | 126 | 142 | 134 | 159 | 190 | 175 | 178 |
65 | 51 | 58 | 58 | 93 | 102 | 101 | 101 | 105 | 118 | 139 | 147 | 154 | |
CWIP | 0 | 7 | 0 | 0 | 11 | 4 | 4 | 3 | 4 | 12 | 8 | 4 | 0 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
83 | 80 | 80 | 50 | 13 | 16 | 21 | 38 | 24 | 29 | 43 | 24 | 24 | |
Total Assets | 149 | 138 | 138 | 108 | 116 | 122 | 126 | 142 | 134 | 159 | 190 | 175 | 178 |
Cash Flows
Figures in Rs. Crores
Mar 2012 | Jun 2013 | Sep 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
7 | -2 | 49 | -45 | -15 | -11 | -6 | 4 | -36 | -15 | -17 | -25 | |
-1 | 6 | 0 | -3 | -4 | -5 | -3 | -4 | -10 | -23 | -23 | -13 | |
-6 | -4 | -49 | 54 | 13 | 16 | 9 | 17 | 29 | 38 | 40 | 37 | |
Net Cash Flow | 0 | -0 | 0 | 6 | -6 | -0 | 0 | 17 | -17 | 1 | -1 | -0 |
Ratios
Figures in Rs. Crores
Mar 2012 | Jun 2013 | Sep 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 41 | 30 | 10 | 180 | 3 | 22 | 2 | 2 | 5 | 4 | ||
Inventory Days | 286 | 2,368 | 14,704 | 2,162 | 337 | 142 | 345 | 234 | 230 | 170 | ||
Days Payable | 256 | 1,517 | 32,250 | 4,360 | 510 | 339 | 521 | 292 | 340 | 217 | ||
Cash Conversion Cycle | 70 | 881 | -17,536 | -2,018 | -170 | -175 | -174 | -57 | -106 | -44 | ||
Working Capital Days | -6 | -446 | -6,532 | -2,132 | -275 | -315 | -267 | -119 | -200 | -162 | ||
ROCE % | -9% | -15% | -4% | -8% | -27% | -27% | -26% | -36% | -57% | -42% | -59% | -29% |
Documents
Announcements
- Submission Of Certificate Under Reg. 40(9) Of SEBI (LODR) Regulations, 2015 For The Year Ended 31.03.2024 18h
-
Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer
15 Apr - Resignation of Mr. Keyur Doshi as Company Secretary and Compliance Officer of the Company.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
8 Apr - Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the Quarter ended 31st March 2024.
- Compliance Certificate Pursuant To Regulation 7(3) Of SEBI (LODR) Regulations, 2015. 8 Apr
-
Disclosure Under Regulation 30 Of The SEBI (LODR) Regulations, 2015.
27 Mar - Additional details in reference to our letter dated 20th October 2023, are enclosed herewith.
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2009
from bse
Product Portfolio
a) Androstenedione which is used as Steroid Intermediate
b) Lovastatin used as Anti-cholesterol medication
c) Simvastatin is also used as Anti-cholesterol medication
d) Upcoming Products: Amlodipine, Cetirizine, Orlistat, Telmisartan, Serratiopepetidase and Phenylephrine. [1]